Blockchain Registration Transaction Record

Kairos Pharma Reports Positive Phase 2 Trial Results for Prostate Cancer Therapy

Kairos Pharma announces positive Phase 2 trial results for ENV-105 in metastatic castration-resistant prostate cancer, showing no dose-limiting toxicities.

This news is significant for patients with metastatic castration-resistant prostate cancer, a condition with limited treatment options. The favorable safety profile of ENV-105, combined with its potential to overcome drug resistance, offers hope for more effective therapies. For the medical community and investors, Kairos Pharma's progress represents a promising advancement in oncology therapeutics, potentially leading to breakthroughs in treating not just prostate cancer but other resistant cancers as well.